Clover Health Investments, Corp. - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Clover Health Investments, Corp. operates as a technology-enabled Medicare Advantage insurer, offering PPO and HMO plans. The company utilizes its proprietary "Clover Assistant" platform to manage chronic diseases and reduce costs. As of March 31, 2026, the company operated in five states with 155,773 members.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $749.2 million | $462.3 million |
| Premiums Earned, Net | $744.2 million | $456.9 million |
| Net Medical Claims Incurred | $589.6 million | $353.4 million |
| Net Income (GAAP) | $27.3 million | ($1.3 million) loss |
| Adjusted EBITDA (Non-GAAP) | $40.3 million | $25.8 million |
| Cash and Cash Equivalents | $173.3 million | $155.4 million |
| Total Investments | $240.7 million | $224.6 million |
| Unpaid Claims Liability | $260.4 million | $153.3 million |
| Benefits Expense Ratio (BER) | 86.5% | 86.1% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by 62.0% ($286.9 million) year-over-year, driven primarily by a 51% increase in average membership and improved Star Ratings (4.0 stars in 2026 vs. 3.5 stars in 2025 for PPO plans).
- Profitability: The company reported a net income of $27.3 million, a significant turnaround from a net loss of $1.3 million in Q1 2025. Operating income improved from a loss of $1.3 million to a profit of $27.3 million.
- Expense Trends: Net medical claims incurred rose 66.8% to $589.6 million, consistent with membership growth. General and administrative expenses increased 47.3% due to higher professional and broker fees. Conversely, salaries and benefits decreased 3.3% due to reduced stock-based compensation ($12.3 million in Q1 2026 vs. $26.4 million in Q1 2025).
- Cash Flow: Net cash provided by operating activities turned positive at $107.9 million, compared to a use of $16.3 million in the prior year. This was largely driven by a $107.2 million increase in unpaid claims liabilities.
Outlook, Risks, and Management Commentary
- Star Ratings: Management highlighted that the company is currently being paid on 4.0 stars for its PPO plans, up from 3.5 stars in the prior period, which significantly boosted premium revenue.
- Technology Expansion: The company continues to expand "Counterpart Health," a SaaS offering of its Clover Assistant technology to external payors and providers.
- Regulatory Environment: The filing notes CMS's intention to significantly increase Risk Adjustment Data Validation (RADV) audits, which poses a risk to revenue recognition.
- Liquidity: Management believes current cash, investments, and projected cash flows are sufficient to meet obligations for the next 12 months. No dividends were paid to the parent company from regulated subsidiaries during the quarter.
- Legal Proceedings: The SEC investigation regarding the 2021 Hindenburg Research article was concluded in September 2024 with no enforcement action recommended. No other material contingent liabilities were identified.
Investor Verification Checklist
- Membership Retention: Verify the sustainability of the 51% membership growth and the impact of the 4.0 Star Rating on future premium rates.
- Claims Development: Monitor the $6.4 million unfavorable claims development recognized in Q1 2026 and the adequacy of the $260.4 million unpaid claims reserve.
- Stock-Based Compensation: Assess the impact of the significant reduction in stock-based compensation ($14.2 million decrease) on future GAAP profitability as vesting schedules change.
- Regulatory Audits: Evaluate the potential financial impact of increased CMS RADV audits on risk adjustment revenue.
- Related Party Transactions: Review ongoing contracts with related parties (e.g., Thyme Care, Credo) for expense trends and potential conflicts of interest.